Ceres, Inc.

Cell and Gene Therapy

Pulmatrix, Inc. | September 27, 2022

Pulmatrix, Inc. a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced that all subjects have completed dosing in a Phase 1 trial evaluating PUR3100, a novel orally inhaled formulation of dihydroergotamine in healthy volunteers. Phase 1 data from this study is expected in Q4 2022. The Phase 1 trial has a double-dummy, double-blinded design to assesses the safety, to...

InvestorsObserver | April 22, 2020

Avid Bioservices Inc (CDMO) is around the top of the Biotechnology industry according to InvestorsObserver. CDMO received an overall rating of 68, which means that it scores higher than 68 percent of all stocks. Avid Bioservices Inc also achieved a score of 76 in the Biotechnology industry, putting it above 76 percent of Biotechnology stocks. Biotechnology is ranked 7 out of the 148 industries. What do These Ratings Mean? Finding the best stocks can be tricky. It isn’t easy to compare comp...

Maravai Lifesciences | August 25, 2020

Maravai LifeSciences, a global provider of life science reagents and services to researchers and biotech innovators, is expanding its contract development and manufacturing organization (CDMO) capabilities at TriLink BioTechnologies for the second time in less than a year. The expansion is expected to be completed in the first quarter of 2021 and will increase TriLink's small molecule manufacturing capacity with a focus on additional scale-up of CleanCap®, its proprietary messenger RNA (...

Medical, Industry Outlook

Globenewswire | August 17, 2023

Mustang Bio Inc. a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced the first data from the indolent lymphoma cohort of the Company’s ongoing multicenter Phase 1/2 clinical trial evaluating MB-106, a first-in-class CD20-targeted, autologous CAR-T cell therapy for the treatment of relapsed or refractory B-cell non-...